Role and research progress of spasmolytic polypeptide‑expressing metaplasia in gastric cancer (Review)

Chong,Yang; Yu,Dong; Lu,Zhaoyu; Nie,Fengsong

doi:10.3892/ijo.2024.5621

Role and research progress of spasmolytic polypeptide‑expressing metaplasia in gastric cancer (Review)

Authors:
- Yang Chong
- Dong Yu
- Zhaoyu Lu
- Fengsong Nie
View Affiliations

Affiliations: Department of Traditional Chinese Medicine, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu 225000, P.R. China
Published online on: February 1, 2024 https://doi.org/10.3892/ijo.2024.5621
Article Number: 33
Copyright: © Chong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer ranks as one of the most prevalent cancers worldwide. While the incidence of gastric cancer in Western countries has notably diminished over the past century, it continues to be a leading cause of cancer‑related mortality on a global scale. The majority of gastric cancers in humans are attributed to chronic Helicobacter pylori infection and the progression of gastric cancer is often preceded by gastritis, atrophy, metaplasia and dysplasia. However, the precise mechanisms underlying the development of gastric cancer remain ambiguous, including the formation of gastric polyps and precancerous lesions. In humans, two types of precancerous metaplasia have been identified in relation to gastric malignancies: Intestinal metaplasia and spasmolytic polypeptide‑expressing metaplasia (SPEM). The role of SPEM in the induction of gastric cancer has gained recent attention and its link with early‑stage human gastric cancer is increasingly evident. To gain insight into SPEM, the present study reviewed the role and research progress of SPEM in gastric cancer.

View Figures

View References

1	Cao W, Chen HD, Yu YW, Li N and Chen WQ: Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 134:783–791. 2021.
2	Kinoshita H, Hayakawa Y and Koike K: Metaplasia in the stomach-precursor of gastric cancer? Int J Mol Sci. 18:20632017.
3	Giroux V and Rustgi AK: Metaplasia: Tissue injury adaptation and a precursor to the dysplasia-cancer sequence. Nat Rev Cancer. 17:594–604. 2017.
4	Weis VG and Goldenring JR: Current understanding of SPEM and its standing in the preneoplastic process. Gastric Cancer. 12:189–197. 2009.
5	Schmidt PH, Lee JR, Joshi V, Playford RJ, Poulsom R, Wright NA and Goldenring JR: Identification of a metaplastic cell lineage associated with human gastric adenocarcinoma. Lab Invest. 79:639–646. 1999.
6	Barros R, Freund JN, David L and Almeida R: Gastric intestinal metaplasia revisited: Function and regulation of CDX2. Trends Mol Med. 18:555–563. 2012.
7	Petersen CP, Weis VG, Nam KT, Sousa JF, Fingleton B and Goldenring JR: Macrophages promote progression of spasmolytic polypeptide-expressing metaplasia after acute loss of parietal cells. Gastroenterology. 146:1727–1738 e8. 2014.
8	Nam KT, Lee HJ, Mok H, Romero-Gallo J, Crowe JE Jr, Peek RM Jr and Goldenring JR: Amphiregulin-deficient mice develop spasmolytic polypeptide expressing metaplasia and intestinal metaplasia. Gastroenterology. 136:1288–1296. 2009.
9	Lefebvre O, Wolf C, Kédinger M, Chenard MP, Tomasetto C, Chambon P and Rio MC: The mouse one P-domain (pS2) and two P-domain (mSP) genes exhibit distinct patterns of expression. J Cell Biol. 122:191–198. 1993.
10	Playford RJ, Marchbank T, Goodlad RA, Chinery RA, Poulsom R and Hanby AM: Transgenic mice that overexpress the human trefoil peptide pS2 have an increased resistance to intestinal damage. Proc Natl Acad Sci USA. 93:2137–2142. 1996.
11	Mills JC and Goldenring JR: Metaplasia in the stomach arises from gastric chief cells. Cell Mol Gastroenterol Hepatol. 4:85–88. 2017.
12	Lennerz JK, Kim SH, Oates EL, Huh WJ, Doherty JM, Tian X, Bredemeyer AJ, Goldenring JR, Lauwers GY, Shin YK and Mills JC: The transcription factor MIST1 is a novel human gastric chief cell marker whose expression is lost in metaplasia, dysplasia, and carcinoma. Am J Pathol. 177:1514–1533. 2010.
13	Wada T, Ishimoto T, Seishima R, Tsuchihashi K, Yoshikawa M, Oshima H, Oshima M, Masuko T, Wright NA, Furuhashi S, et al: Functional role of CD44v-xCT system in the development of spasmolytic polypeptide-expressing metaplasia. Cancer Sci. 104:1323–1329. 2013.
14	Bertaux-Skeirik N, Wunderlich M, Teal E, Chakrabarti J, Biesiada J, Mahe M, Sundaram N, Gabre J, Hawkins J, Jian G, et al: CD44 variant isoform 9 emerges in response to injury and contributes to the regeneration of the gastric epithelium. J Pathol. 242:463–475. 2017.
15	Karam SM and Leblond CP: Identifying and counting epithelial cell types in the 'corpus' of the mouse stomach. Anat Rec. 232:231–246. 1992.
16	Hayakawa Y, Ariyama H, Stancikova J, Sakitani K, Asfaha S, Renz BW, Dubeykovskaya ZA, Shibata W, Wang H, Westphalen CB, et al: Mist1 expressing gastric stem cells maintain the normal and neoplastic gastric epithelium and are supported by a perivascular stem cell niche. Cancer Cell. 28:800–814. 2015.
17	Matsuo J, Kimura S, Yamamura A, Koh CP, Hossain MZ, Heng DL, Kohu K, Voon DC, Hiai H, Unno M, et al: Identification of stem cells in the epithelium of the stomach corpus and antrum of mice. Gastroenterology. 152:218–231 e14. 2017.
18	Caldwell B, Meyer AR, Weis JA, Engevik AC and Choi E: Chief cell plasticity is the origin of metaplasia following acute injury in the stomach mucosa. Gut. 71:1068–1077. 2022.
19	Radyk MD, Burclaff J, Willet SG and Mills JC: Metaplastic cells in the stomach arise, independently of stem cells, via dedifferentiation or transdifferentiation of chief cells. Gastroenterology. 154:839–843 e2. 2018.
20	Hayakawa Y, Fox YG and Wang TC: Isthmus stem cells are the origins of metaplasia in the gastric corpus. Cell Mol Gastroenterol Hepatol. 4:89–94. 2017.
21	Sáenz JB and Mills JC: Acid and the basis for cellular plasticity and reprogramming in gastric repair and cancer. Nat Rev Gastroenterol Hepatol. 15:257–273. 2018.
22	Goldenring JR and Nam KT: Oxyntic atrophy, metaplasia, and gastric cancer. Prog Mol Biol Transl Sci. 96:117–131. 2010.
23	Blaser MJ and Parsonnet J: Parasitism by the 'slow' bacterium Helicobacter pylori leads to altered gastric homeostasis and neoplasia. J Clin Invest. 94:4–8. 1994.
24	Jain RN, Brunkan CS, Chew CS and Samuelson LC: Gene expression profiling of gastrin target genes in parietal cells. Physiol Genomics. 24:124–132. 2006.
25	Beauchamp RD, Barnard JA, McCutchen CM, Cherner JA and Coffey RJ Jr: Localization of transforming growth factor alpha and its receptor in gastric mucosal cells. Implications for a regulatory role in acid secretion and mucosal renewal. J Clin Invest. 84:1017–1023. 1989.
26	Murayama Y, Miyagawa J, Higashiyama S, Kondo S, Yabu M, Isozaki K, Kayanoki Y, Kanayama S, Shinomura Y, Taniguchi N, et al: Localization of heparin-binding epidermal growth factor-like growth factor in human gastric mucosa. Gastroenterology. 109:1051–1059. 1995.
27	Abe S, Sasano H, Katoh K, Ohara S, Arikawa T, Noguchi T, Asaki S, Yasui W, Tahara E, Nagura H and Toyota T: Immunohistochemical studies on EGF family growth factors in normal and ulcerated human gastric mucosa. Dig Dis Sci. 42:1199–1209. 1997.
28	El-Zimaity HM, Ota H, Graham DY, Akamatsu T and Katsuyama T: Patterns of gastric atrophy in intestinal type gastric carcinoma. Cancer. 94:1428–1436. 2002.
29	Filipe MI, Muñoz N, Matko I, Kato I, Pompe-Kirn V, Jutersek A, Teuchmann S, Benz M and Prijon T: Intestinal metaplasia types and the risk of gastric cancer: A cohort study in Slovenia. Int J Cancer. 57:324–329. 1994.
30	Xia HH, Kalantar JS, Talley NJ, Wyatt JM, Adams S, Chueng K and Mitchell HM: Antral-type mucosa in the gastric incisura, body, and fundus (antralization): A link between Helicobacter pylori infection and intestinal metaplasia? Am J Gastroenterol. 95:114–121. 2000.
31	Yamaguchi H, Goldenring JR, Kaminishi M and Lee JR: Association of spasmolytic polypeptide-expressing metaplasia with carcinogen administration and oxyntic atrophy in rats. Lab Invest. 82:1045–1052. 2002.
32	Halldórsdóttir AM, Sigurdardóttrir M, Jónasson JG, Oddsdóttir M, Magnússon J, Lee JR and Goldenring JR: Spasmolytic polypeptide-expressing metaplasia (SPEM) associated with gastric cancer in iceland. Dig Dis Sci. 48:431–441. 2003.
33	Yamaguchi H, Goldenring JR, Kaminishi M and Lee JR: Identification of spasmolytic polypeptide expressing metaplasia (SPEM) in remnant gastric cancer and surveillance postgastrectomy biopsies. Dig Dis Sci. 47:573–578. 2002.
34	Goldenring JR and Nomura S: Differentiation of the gastric mucosa III. Animal models of oxyntic atrophy and metaplasia. Am J Physiol Gastrointest Liver Physiol. 291:G999–G1004. 2006.
35	Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, et al: Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 66:6–30. 2017.
36	Kuo HY, Chang WL, Yeh YC, Cheng HC, Tsai YC, Wu CT, Lin SH, Yang HB, Lu CC and Sheu BS: Spasmolytic polypeptide-expressing metaplasia associated with higher expressions of miR-21, 155, and 223 can be regressed by Helicobacter pylori eradication in the gastric cancer familial relatives. Helicobacter. 24:e125782019.
37	Ogawa M, Nomura S, Car BD and Goldenring JR: Omeprazole treatment ameliorates oxyntic atrophy induced by DMP-777. Dig Dis Sci. 51:431–439. 2006.
38	Nam KT, Lee HJ, Sousa JF, Weis VG, O'Neal RL, Finke PE, Romero-Gallo J, Shi G, Mills JC, Peek RM Jr, et al: Mature chief cells are cryptic progenitors for metaplasia in the stomach. Gastroenterology. 139:2028–2037.e9. 2010.
39	Weis VG, Sousa JF, LaFleur BJ, Nam KT, Weis JA, Finke PE, Ameen NA, Fox JG and Goldenring JR: Heterogeneity in mouse spasmolytic polypeptide-expressing metaplasia lineages identifies markers of metaplastic progression. Gut. 62:1270–1279. 2013.
40	Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H, Cai X, Fox JG, Goldenring JR and Wang TC: Gastric cancer originating from bone marrow-derived cells. Science. 306:1568–1571. 2004.
41	Goldenring JR, Ray GS, Coffey RJ, Meunier PC, Haley PJ, Barnes TB and Car BD: Reversible drug-induced oxyntic atrophy in rats. Gastroenterology. 118:1080–1093. 2000.
42	Nomura S, Yamaguchi H, Ogawa M, Wang TC, Lee JR and Goldenring JR: Alterations in gastric mucosal lineages induced by acute oxyntic atrophy in wild-type and gastrin-deficient mice. Am J Physiol Gastrointest Liver Physiol. 288:G362–G375. 2005.
43	Nozaki K, Ogawa M, Williams JA, Lafleur BJ, Ng V, Drapkin RI, Mills JC, Konieczny SF, Nomura S and Goldenring JR: A molecular signature of gastric metaplasia arising in response to acute parietal cell loss. Gastroenterology. 134:511–522. 2008.
44	Nam KT, Varro A, Coffey RJ and Goldenring JR: Potentiation of oxyntic atrophy-induced gastric metaplasia in amphiregulin-deficient mice. Gastroenterology. 132:1804–1819. 2007.
45	Muthupalani S, Ge Z, Joy J, Feng Y, Dobey C, Cho HY, Langenbach R, Wang TC, Hagen SJ and Fox JG: Muc5ac null mice are predisposed to spontaneous gastric antro-pyloric hyperplasia and adenomas coupled with attenuated H. pylori-induced corpus mucous metaplasia. Lab Invest. 99:1887–1905. 2019.
46	Busada JT, Ramamoorthy S, Cain DW, Xu X, Cook DN and Cidlowski JA: Endogenous glucocorticoids prevent gastric metaplasia by suppressing spontaneous inflammation. J Clin Invest. 129:1345–1358. 2019.
47	Biswas SK and Mantovani A: Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nat Immunol. 11:889–896. 2010.
48	Hanna RN, Cekic C, Sag D, Tacke R, Thomas GD, Nowyhed H, Herrley E, Rasquinha N, McArdle S, Wu R, et al: Patrolling monocytes control tumor metastasis to the lung. Science. 350:985–990. 2015.
49	Papierska L and Rabijewski M: Delay in diagnosis of adrenal insufficiency is a frequent cause of adrenal crisis. Int J Endocrinol. 2013:4823702013.
50	Puar TH, Stikkelbroeck NM, Smans LC, Zelissen PM and Hermus AR: Adrenal crisis: still a deadly event in the 21st century. Am J Med. 129:339 e1–9. 2016.
51	Meyer AR, Engevik AC, Madorsky T, Belmont E, Stier MT, Norlander AE, Pilkinton MA, McDonnell WJ, Weis JA, Jang B, et al: Group 2 innate lymphoid cells coordinate damage response in the stomach. Gastroenterology. 159:2077–2091.e8. 2020.
52	Meyer AR and Goldenring GR: Injury, repair, inflammation and metaplasia in the stomach. J Physiol. 596:3861–3867. 2018.
53	Goldenring JR, Nam KT, Wang TC, Mills JC and Wright NA: Spasmolytic polypeptide-expressing metaplasia and intestinal metaplasia: Time for reevaluation of metaplasias and the origins of gastric cancer. Gastroenterology. 138:2207–2210.e1. 2010.
54	Hayakawa Y and Wang TC: Isthmus Progenitors, not chief cells, are the likely origin of metaplasia in eR1-CreERT; LSL-Kras^G12D Mice. Gastroenterology. 152:2078–2079. 2017.
55	Hayakawa Y, Fox JG and Wang TC: The origins of gastric cancer from gastric stem cells: Lessons from mouse models. Cell Mol Gastroenterol Hepatol. 3:331–338. 2017.
56	Nomura S, Baxter T, Yamaguchi H, Leys C, Vartapetian AB, Fox JG, Lee JR, Wang TC and Goldenring JR: Spasmolytic polypeptide expressing metaplasia to preneoplasia in H. felis-infected mice. Gastroenterology. 127:582–594. 2004.
57	Kinoshita H, Hayakawa Y, Niu Z, Konishi M, Hata M, Tsuboi M, Hayata Y, Hikiba Y, Ihara S, Nakagawa H, et al: Mature gastric chief cells are not required for the development of metaplasia. Am J Physiol Gastrointest Liver Physiol. 314:G583–G596. 2018.
58	Hata M, Kinoshita H, Hayakawa Y, Konishi M, Tsuboi M, Oya Y, Kurokawa K, Hayata Y, Nakagawa H, Tateishi K, et al: GPR30-Expressing gastric chief cells do not dedifferentiate but are eliminated via PDK-Dependent cell competition during development of metaplasia. Gastroenterology. 158:1650–1666 e15. 2020.
59	Nam KT, O'Neal RL, Coffey RJ, Finke PE, Barker N and Goldenring JR: Spasmolytic polypeptide-expressing metaplasia (SPEM) in the gastric oxyntic mucosa does not arise from Lgr5-expressing cells. Gut. 61:1678–1685. 2012.
60	Meyer AR, Engevik AC, Willet SG, Williams JA, Zou Y, Massion PP, Mills JC, Choi E and Goldenring JR: Cystine/Glutamate Antiporter (xCT) is required for chief cell plasticity after gastric injury. Cell Mol Gastroenterol Hepatol. 8:379–405. 2019.
61	Lee A, O'Rourke J, De Ungria MC, Robertson B, Daskalopoulos G and Dixon MF: A standardized mouse model of Helicobacter pylori infection: Introducing the Sydney strain. Gastroenterology. 112:1386–1397. 1997.
62	Watanabe T, Tada M, Nagai H, Sasaki S and Nakao M: Helicobacter pylori infection induces gastric cancer in Mongolian gerbils. Gastroenterology. 115:642–648. 1998.
63	Lee JR, Baxter TM, Yamaguchi H, Wang TC, Goldenring JR and Anderson MG: Differential protein analysis of spasomolytic polypeptide expressing metaplasia using laser capture microdissection and two-dimensional difference gel electrophoresis. Appl Immunohistochem Mol Morphol. 11:188–193. 2003.
64	Yoshizawa N, Takenaka Y, Yamaguchi H, Tetsuya T, Tanaka H, Tatematsu M, Nomura S, Goldenring JR and Kaminishi M: Emergence of spasmolytic polypeptide-expressing metaplasia in Mongolian gerbils infected with Helicobacter pylori. Lab Invest. 87:1265–1276. 2007.
65	El-Zimaity HM, Ramchatesingh J, Saeed MA and Graham DY: Gastric intestinal metaplasia: Subtypes and natural history. J Clin Pathol. 54:679–683. 2001.
66	Matsukura N, Kinebuchi M, Kawachi T, Sato S and Sugimura T: Quantitative measurement of intestinal marker enzymes in intestinal metaplasia from human stomach with cancer. Gan. 70:509–513. 1979.
67	Ricardo SD, van Goor H and Eddy AA: Macrophage diversity in renal injury and repair. J Clin Invest. 118:3522–3530. 2008.
68	Mills CD, Kincaid K, Alt JM, Heilman MJ and Hill AM: M-1/M-2 Macrophages and the Th1/Th2 Paradigm. J Immunol. 164:6166–6173. 2000.
69	Teal E, Dua-Awereh M, Hirshorn ST and Zavros Y: Role of metaplasia during gastric regeneration. Am J Physiol Cell Physiol. 319:C947–C954. 2020.
70	Petersen CP, Meyer AR, De Salvo C, Choi E, Schlegel C, Petersen A, Engevik AC, Prasad N, Levy SE, Peebles RS, et al: A signalling cascade of IL-33 to IL-13 regulates metaplasia in the mouse stomach. Gut. 67:805–817. 2018.
71	De Salvo C, Pastorelli L, Petersen CP, Buttò LF, Buela KA, Omenetti S, Locovei SA, Ray S, Friedman HR, Duijser J, et al: Interleukin 33 triggers early eosinophil-dependent events leading to metaplasia in a chronic model of gastritis-prone mice. Gastroenterology. 160:302–316 e7. 2021.
72	Xu X, Cheng J, Luo S, Gong X, Huang D, Xu J, Qian Y, Wan X and Zhou H: Deoxycholic acid-stimulated macrophage-derived exosomes promote spasmolytic polypeptide-expressing metaplasia in the stomach. Biochem Biophys Res Commun. 524:649–655. 2020.
73	Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q and Dong C: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 6:1133–1141. 2005.
74	Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM and Weaver CT: Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 6:1123–1132. 2005.
75	Onishi RM and Gaffen SL: Interleukin-17 and its target genes: Mechanisms of interleukin-17 function in disease. Immunology. 129:311–321. 2010.
76	Bockerstett KA, Osaki LH, Petersen CP, Cai CW, Wong CF, Nguyen TM, Ford EL, Hoft DF, Mills JC, Goldenring JR and DiPaolo RJ: Interleukin-17A promotes parietal cell atrophy by inducing apoptosis. Cell Mol Gastroenterol Hepatol. 5:678–690 e1. 2018.
77	Togawa S, Joh T, Itoh M, Katsuda N, Ito H, Matsuo K, Tajima K and Hamajima N: Interleukin-2 gene polymorphisms associated with increased risk of gastric atrophy from helicobacter pylori infection. Helicobacter. 10:172–178. 2005.
78	Sugimoto M, Yamaoka Y and Furuta T: Influence of interleukin polymorphisms on development of gastric cancer and peptic ulcer. World J Gastroenterol. 16:1188–1200. 2010.
79	Yamaoka Y, Kodama T, Kita M, Imanishi J, Kashima K and Graham DY: Relation between clinical presentation, Helicobacter pylori density, interleukin 1beta and 8 production, and cagA status. Gut. 45:804–811. 1999.
80	Lee C, Lee H, Hwang SY, Moon CM and Hong SN: IL-10 Plays a pivotal role in tamoxifen-induced spasmolytic polypeptide-expressing metaplasia in gastric mucosa. Gut Liver. 11:789–797. 2017.
81	Maloum F, Allaire JM, Gagné-Sansfaçon J, Roy E, Belleville K, Sarret P, Morisset J, Carrier JC, Mishina Y, Kaestner KH and Perreault N: Epithelial BMP signaling is required for proper specification of epithelial cell lineages and gastric endocrine cells. Am J Physiol Gastrointest Liver Physiol. 300:G1065–G1079. 2011.
82	Bleuming SA, He XC, Kodach LL, Hardwick JC, Koopman FA, Ten Kate FJ, van Deventer SJ, Hommes DW, Peppelenbosch MP, Offerhaus GJ, et al: Bone morphogenetic protein signaling suppresses tumorigenesis at gastric epithelial transition zones in mice. Cancer Res. 67:8149–8155. 2007.
83	Oshima H, Itadani H, Kotani H, Taketo MM and Oshima M: Induction of prostaglandin E2 pathway promotes gastric hamartoma development with suppression of bone morphogenetic protein signaling. Cancer Res. 69:2729–2733. 2009.
84	Auclair BA, Benoit YD, Rivard N, Mishina Y and Perreault N: Bone morphogenetic protein signaling is essential for terminal differentiation of the intestinal secretory cell lineage. Gastroenterology. 133:887–896. 2007.
85	Oshima H and Oshima M: Mouse models of gastric tumors: Wnt activation and PGE2 induction. Pathol Int. 60:599–607. 2010.
86	Liu Z, Demitrack ES, Keeley TM, Eaton KA, El-Zaatari M, Merchant JL and Samuelson LC: IFNү contributes to the development of gastric epithelial cell metaplasia in Huntingtin interacting protein 1 related (Hip1r)-deficient mice. Lab Invest. 92:1045–1057. 2012.
87	Wang TC, Dangler CA, Chen D, Goldenring JR, Koh T, Raychowdhury R, Coffey RJ, Ito S, Varro A, Dockray GJ and Fox JG: Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology. 118:36–47. 2000.
88	Mohammadi M, Czinn S, Redline R and Nedrud J: Helicobacter-specific cell-mediated immune responses display a predominant Th1 phenotype and promote a delayed-type hypersensitivity response in the stomachs of mice. J Immunol. 156:47291996.
89	Roth KA, Kapadia SB, Martin SM and Lorenz RG: Cellular immune responses are essential for the development of helicobacter felis-Associated gastric pathology. J Immunol. 163:14901999.
90	Srivastava S, Huang KK, Rebbani K, Das K, Fazreen Z, Yeoh KG, Tan P and The M: An LCM-based genomic analysis of SPEM, gastric cancer and pyloric gland adenoma in an Asian cohort. Mod Pathol. 33:2075–2086. 2020.
91	Hernandez C, Huebener P and Schwabe RF: Damage-associated molecular patterns in cancer: A double-edged sword. Oncogene. 35:5931–5941. 2016.
92	Otani K, Tanigawa T, Watanabe T, Nadatani Y, Sogawa M, Yamagami H, Shiba M, Watanabe K, Tominaga K, Fujiwara Y and Arakawa T: Toll-like receptor 9 signaling has anti-inflammatory effects on the early phase of Helicobacter pylori-induced gastritis. Biochem Biophys Res Commun. 426:342–349. 2012.
93	Varga MG, Piazuelo MB, Romero-Gallo J, Delgado AG, Suarez G, Whitaker ME, Krishna US, Patel RV, Skaar EP, Wilson KT, et al: TLR9 activation suppresses inflammation in response to Helicobacter pylori infection. Am J Physiol Gastrointest Liver Physiol. 311:G852–G858. 2016.
94	Varga MG, Shaffer CL, Sierra JC, Suarez G, Piazuelo MB, Whitaker ME, Romero-Gallo J, Krishna US, Delgado A, Gomez MA, et al: Pathogenic Helicobacter pylori strains translocate DNA and activate TLR9 via the cancer-associated cag type IV secretion system. Oncogene. 35:6262–6269. 2016.
95	Wang X, Xue L, Yang Y, Xu L and Zhang G: TLR9 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. PLoS One. 8:e657312013.
96	Min J, Han TS, Sohn Y, Shimizu T, Choi B, Bae SW, Hur K, Kong SH, Suh YS, Lee HJ, et al: microRNA-30a arbitrates intestinal-type early gastric carcinogenesis by directly targeting ITGA2. Gastric Cancer. 23:600–613. 2020.
97	Riera KM, Jang B, Min J, Roland JT, Yang Q, Fesmire WT, Camilleri-Broet S, Ferri L, Kim WH, Choi E and Goldenring JR: Trop2 is upregulated in the transition to dysplasia in the metaplastic gastric mucosa. J Pathol. 251:336–347. 2020.
98	Fox JG and Wang TC: Inflammation, atrophy, and gastric cancer. J Clin Invest. 117:60–69. 2007.
99	Correa P: Human gastric carcinogenesis: A multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 52:6735–6740. 1992.
100	Thompson MP and Kurzrock R: Epstein-Barr virus and cancer. Clin Cancer Res. 10:803–821. 2004.
101	Murphy G, Pfeiffer R, Camargo MC and Rabkin CS: Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology. 137:824–833. 2009.
102	Cancer Genome Atlas Research Network: Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 513:202–209. 2014.
103	Lee JH, Kim SH, Han SH, An JS, Lee ES and Kim YS: Clinicopathological and molecular characteristics of Epstein-Barr virus-associated gastric carcinoma: A meta-analysis. J Gastroenterol Hepatol. 24:354–365. 2009.
104	Zhang Y, Chen JN, Dong M, Zhang ZG, Zhang YW, Wu JY, Du H, Li HG, Huang Y and Shao CK: Clinical significance of spasmolytic polypeptide-expressing metaplasia and intestinal metaplasia in Epstein-Barr virus-associated and Epstein-Barr virus-negative gastric cancer. Hum Pathol. 63:128–138. 2017.
105	Gessner R and Tauber R: Intestinal cell adhesion molecules: liver-intestine cadherin. Ann NY Acad Sci. 915:136–143. 2000.
106	Lee HJ, Nam KT, Park HS, Kim MA, Lafleur BJ, Aburatani H, Yang HK, Kim WH and Goldenring JR: Gene expression profiling of metaplastic lineages identifies CDH17 as a prognostic marker in early stage gastric cancer. Gastroenterology. 139:213–725.e3. 2010.
107	O'Neal RL, Nam KT, LaFleur BJ, Barlow B, Nozaki K, Lee HJ, Kim WH, Yang HK, Shi C, Maitra A, et al: Human epididymis protein 4 is up-regulated in gastric and pancreatic adenocarcinomas. Hum Pathol. 44:734–742. 2013.
108	Sousa JF, Ham AJ, Whitwell C, Nam KT, Lee HJ, Yang HK, Kim WH, Zhang B, Li M, LaFleur B, et al: Proteomic profiling of paraffin-embedded samples identifies metaplasia-specific and early-stage gastric cancer biomarkers. Am J Pathol. 181:1560–1572. 2012.
109	Merchant JL and Ding L: Hedgehog signaling links chronic inflammation to gastric cancer precursor lesions. Cell Mol Gastroenterol Hepatol. 3:201–210. 2017.
110	Bockerstett KA, Lewis SA, Noto CN, Ford EL, Saenz JB, Jackson NM, Ahn TH, Mills JC and DiPaolo RJ: Single-Cell transcriptional analyses identify lineage-specific epithelial responses to inflammation and metaplastic development in the gastric corpus. Gastroenterology. 159:2116–2129 e4. 2020.
111	Lee SH, Jang B, Min J, Contreras-Panta EW, Presentation KS, Delgado AG, Piazuelo MB, Choi E and Goldenring JR: Up-regulation of aquaporin 5 defines spasmolytic polypeptide-expressing metaplasia and progression to incomplete intestinal metaplasia. Cell Mol Gastroenterol Hepatol. 13:199–217. 2022.